How many lives could these drugs save, and who currently gets them?
The potential public health benefit is enormous. One study estimates that if all eligible US adults had access to GLP-1 receptor agonists (like semaglutide and tirzepatide), over 42,000 deaths could be prevented each year, including more than 11,000 among people with type 2 diabetes [3]. That is a massive, avoidable death toll—comparable to many common cancers. But the same study emphasizes that this benefit is only theoretical unless barriers like cost and insurance coverage are removed [3].
Who actually gets these drugs today? A large Norwegian study of over 150,000 people who started taking semaglutide for weight loss found that users were more likely to have multiple health problems—71% to 78% had at least one obesity-related complication like hypertension or sleep apnea, compared to about 50% of the general population [1]. That sounds like the right people are getting treated. However, the same study revealed a key inequality: having only a basic education (10 years or less) was more common among users of most weight loss drugs than among the general population—except for users of tirzepatide, the newest and most expensive drug, whose education level matched the general population [1]. This suggests that the most effective (and costly) treatments may be skewing toward more privileged groups.
Why do these drugs widen inequality? Cost, insurance, and the rebound problem.
The core driver is simple: these drugs are expensive, and many health systems cannot afford to cover them for everyone who qualifies. One expert commentary notes that the high cost of GLP-1 agonists, combined with the fact that nearly 1 billion people worldwide have obesity-related sleep apnea, means that universal healthcare systems can only offer subsidized access under strict criteria—effectively rationing care [2]. This inevitably creates a two-tier system: those who can pay out-of-pocket get the drugs; those who cannot, do not.
A second mechanism is the "rebound weight gain" problem. When patients stop taking these drugs, they typically regain about two-thirds of the lost weight within a year [2]. This means treatment is effectively lifelong for sustained benefit, which multiplies the cost burden. For a patient without insurance coverage, the cumulative expense becomes prohibitive, making it a therapy primarily for the wealthy.
A third, more subtle mechanism is that unequal access to new medical technologies is a well-documented pattern. One paper on the opioid crisis applies "Fundamental Cause Theory," which states that in unequal societies, new health technologies tend to benefit privileged groups first, widening disparities unless interventions are explicitly designed to counter that [5]. The authors warn that any new treatment—whether for addiction or obesity—that is not paired with equity-focused policies will likely worsen existing inequalities [5].
Can we fix the inequality, or is the problem bigger than the drugs?
Some researchers argue that focusing solely on medications risks ignoring the root causes of obesity. A 2026 commentary points out that relying on drugs diverts attention from the "structural drivers" of obesity—like the widespread availability of ultra-processed foods and limited access to healthy, affordable food [6]. The authors call for population-level action: mandatory reformulation of processed foods, marketing restrictions, and making nutritious foods more affordable [6]. Medications can help individuals, but only comprehensive food-system reform can sustainably reduce obesity and diet-related disease across all income levels [6].
Other experts emphasize that if we do use these drugs, we must design access policies that explicitly reduce inequality. For example, prioritizing subsidized access for those with the most severe obesity and multiple complications, and ensuring that lower-income patients are not priced out [2][4]. The Norwegian study authors conclude that countries with universal healthcare "must address the high cost of obesity treatments and mitigate health disparities to ensure access for those most likely to benefit" [1]. In short, the drugs themselves are not inherently inequitable—but the way they are priced, insured, and distributed in an unequal society almost certainly will be, unless deliberate countermeasures are taken.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2023 to 2026, 5 from 2024 or later, 5 in Q1 journals, collectively cited 113 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 45 papers retrieved from a database of over 500 million.
Sources used in this answer
Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study.
In a large Norwegian population-based study of over 150,000 weight-loss drug users, users had more comorbidities than controls, but those on the newest drug (tirzepatide) had education levels similar to the general population, suggesting unequal access by socioeconomic status.
The potential impact of <scp>GLP</scp>‐1 agonists on obstructive sleep apnoea
This expert commentary on GLP-1 agonists for sleep apnea warns that the high cost and high prevalence of obesity mean universal healthcare systems cannot afford these drugs for all, which will exacerbate inequities between lower and higher socioeconomic groups.
Estimating the lives that could be saved by expanded access to weight-loss drugs
This modeling study estimates that expanding access to GLP-1 agonists in the US could avert over 42,000 deaths annually, including more than 11,000 among people with type 2 diabetes, highlighting the huge public health stakes of unequal access.
Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity
This commentary notes that GLP-1 receptor agonists are less accessible for obesity than for diabetes worldwide, reflecting biases and lack of education, and perpetuating health inequalities.
Understanding and Addressing Widening Racial Inequalities in Drug Overdose
This paper on racial inequalities in drug overdose applies Fundamental Cause Theory, arguing that new health technologies typically benefit privileged groups first and widen inequalities unless interventions are explicitly designed to counter that.
Fixing the Food Environment: Beyond Weight-Loss Drugs.
This 2026 commentary argues that reliance on weight-loss drugs risks diverting attention from structural drivers of obesity (like ultra-processed food availability) and calls for comprehensive food-system reform to sustainably reduce obesity and diet-related disease.